In the phase 2 TUXEDO-1 trial, T-DXd provided a high intracranial response rate (73.3%; 95% CI, 48.1–89.1) among patients with active brain metastases from HER2+ BC (11). This evidence concerns the gene ERBB2 and breast cancer.